Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the successful close of an oversubscribed $45M financing led by new investor Gilde Healthcare with participation from existing investors including Vensana Capital and U.S. Venture Partners.
Proceeds from the financing will be used to expand the company’s commercial footprint and advance its clinical programs in support of Okami’s mission to improve outcomes for patients suffering from vascular disease. The funding will also support continued innovation of the company’s versatile, intuitive devices designed for the occlusion of peripheral vessels.
Read More – Agentio Raises $40M in Series B Funding
Concurrent with the financing, Drew Hykes, former CEO of Inari Medical, was appointed President and CEO of Okami, while Bill Hoffman was appointed Chairman of the Board.
“I’m honored to join the Okami team and have been deeply impressed by the clinical performance and versatility of the LOBO vascular occluder across a wide range of anatomies,” said Drew Hykes, Chief Executive Officer of Okami Medical. “I look forward to working with this talented team to accelerate our commercial expansion, advance our innovation pipeline, and bring this important technology to more physicians and patients.”
As part of the financing, Geoff Pardo and Susana Amorim of Gilde Healthcare have joined Okami Medical’s Board of Directors. “We have followed Okami for years and have been impressed by the strength of its technology and the scale of its market opportunity,” said Geoff Pardo, General Partner at Gilde Healthcare. “We are pleased to partner with Drew again following our success at Inari and to collaborate with a highly experienced syndicate. We believe Okami’s LOBO platform has the potential to transform treatment and significantly improve outcomes for patients with serious unmet needs.”
Read More – UbiQD Receives $6M in Growth Financing
